Brind.

A business update detailing the robust performance of CAG Diagnostics, strong gains in consumable revenues, and the delivery of cloud-native PIMS platforms.

2 reports, 1 independent Updated Aug 27
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A business update detailing the robust performance of CAG Diagnostics, strong gains in consumable revenues, and the delivery of cloud-native PIMS platforms.

Who's involved

What this event is mainly about
IDEXX Laboratories, Inc.

How it developed

Newest first. Tap a step to see who reported it.
  1. Performance report on CAG Diagnostics business unit, including revenue gains and cloud product delivery.1 source
  2. IDEXX growth driven by gains at Catalyst and inclusion of NEO in PIMS platforms.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksShould You Add IDEXX Stock to Your Portfolio Right Now? IDEXX Laboratories, Inc.’s IDXX second-quarter growth was backed by the robust performance of its CAG (Companion Animal Group) Diagnostics busi
  • ZacksIDEXX Gains 56.2% in a Year: What's Driving the Rally? IDEXX Laboratories IDXX has witnessed strong momentum year to date. Shares of the company have risen 56.2%, outperforming the 6.8% decline of th